Stage III Cutaneous Melanoma AJCC v7

Showing 1 - 17 of 17

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma, Metastatic Non-Cutaneous Melanoma Trial in Canada, Ireland, United

Active, not recruiting
  • Metastatic Cutaneous Melanoma
  • +15 more
  • Ipilimumab
  • +3 more
  • Birmingham, Alabama
  • +582 more
Jan 28, 2023

Advanced Malignant Solid Tumor, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7 Trial in New Brunswick

Active, not recruiting
  • Advanced Malignant Solid Neoplasm
  • +9 more
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
Jan 25, 2023

Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma Trial in

Active, not recruiting
  • Metastatic Melanoma
  • +22 more
  • Ipilimumab
  • +3 more
  • Birmingham, Alabama
  • +24 more
Jan 19, 2023

Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 Trial in Rochester (drug,

Active, not recruiting
  • Metastatic Melanoma
  • +6 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 13, 2023

Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7 Trial in

Active, not recruiting
  • Stage III Cutaneous Melanoma AJCC v7
  • +4 more
  • Cryosurgery
  • +3 more
  • Rochester, Minnesota
    Mayo Clinic
Jan 3, 2023

Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7 Trial in

Completed
  • Stage III Cutaneous Melanoma AJCC v7
  • +5 more
  • Aldesleukin
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 17, 2022

Advanced Melanoma, Melanoma of Unknown Primary, Mucosal Melanoma Trial in United States (Ipilimumab, Nivolumab)

Active, not recruiting
  • Advanced Melanoma
  • +10 more
  • Ipilimumab
  • Nivolumab
  • Anchorage, Alaska
  • +638 more
Aug 30, 2022

Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7 Trial in Houston

Active, not recruiting
  • Metastatic Melanoma
  • +2 more
  • Aldesleukin
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma Trial in United States

Active, not recruiting
  • Stage III Cutaneous Melanoma AJCC v7
  • +2 more
  • Computed Tomography
  • +3 more
  • Birmingham, Alabama
  • +759 more
Aug 18, 2022

BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Tumor Trial in Boston (Dabrafenib,

Active, not recruiting
  • BRAF V600E Mutation Present
  • +9 more
  • Boston, Massachusetts
  • +1 more
Jun 28, 2022

Metastatic Malignant Tumor in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7 Trial in Houston (drug,

Active, not recruiting
  • Metastatic Malignant Neoplasm in the Brain
  • +7 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 15, 2022

BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma Trial in Boston (drug, biological, other)

Terminated
  • BRAF V600E Mutation Present
  • +7 more
  • Boston, Massachusetts
  • +1 more
Mar 9, 2022

Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary Trial in United States (DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly

Completed
  • Cutaneous Melanoma
  • +11 more
  • DEC-205/NY-ESO-1 Fusion Protein CDX-1401
  • +2 more
  • Chicago, Illinois
  • +6 more
Nov 10, 2021

Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 Trial in Los Angeles, Salt Lake

Terminated
  • Metastatic Melanoma
  • +5 more
  • Anti-SEMA4D Monoclonal Antibody VX15/2503
  • +4 more
  • Los Angeles, California
  • +1 more
Apr 1, 2021

Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 Trial in Houston (biological,

Recruiting
  • Metastatic Melanoma
  • +5 more
  • Aldesleukin
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 10, 2020

Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7 Trial in United States (Aldesleukin, Laboratory

Completed
  • Metastatic Melanoma
  • +6 more
  • Aldesleukin
  • +2 more
  • Duarte, California
  • +20 more
May 9, 2019

Advanced Malignant Solid Tumor, Estrogen Receptor Negative, GPNMB Positive Trial (drug, biological, other)

Withdrawn
  • Advanced Malignant Solid Neoplasm
  • +17 more
  • Glembatumumab Vedotin
  • +4 more
  • (no location specified)
Jul 17, 2018